SynthesisReviews in cardiovascular medicine2025
Effects of Perioperative Recombinant Human Brain Natriuretic Peptide in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis.
Synthesis in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07617675 (Perioperative Recombinant Human Brain Natriuretic Peptide for Renal Protection in Cardiac Surgery), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Perioperative Recombinant Human Brain Natriuretic Peptide for Renal Protection in Cardiac Surgery: the PROTECT-CS Randomized Clinical Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clinical trials have demonstrated the efficacy of recombinant human brain natriuretic peptide (rhBNP) in managing acute decompensated heart failure. Moreover, since rhBNP performs roles in hemodynamic regulation, neurohormonal balance, and renal function, rhBNP administration could benefit cardiac surgery patients. We conducted a systematic review and meta-analysis to evaluate the impact of perioperative rhBNP in cardiac surgery patients. Methods: We conducted a comprehensive search of the MEDLINE, Embase, the Cochrane Library, CNKI, and WANFANG databases from January 1, 2007, until December 31, 2023, identifying randomized controlled trials (RCTs) that examined the use of rhBNP during cardiac surgery. We estimated the treatment effects of perioperative rhBNP administration using a random-effects meta-analysis. The primary cardiovascular endpoint was the change in left ventricular ejection fraction (LVEF); meanwhile, renal function was assessed using the 24-hour urine output, changes in estimated glomerular filtration rate (eGFR), and serum creatinine (SCr) levels. Additional parameters included pulmonary artery pressure (PAP), adverse event (AE) incidence, respiratory support duration, ICU length of stay (ICU LOS), hospital length of stay (hospital LOS), and tumor necrosis factor-α (TNF-α) levels. Results: Our meta-analysis included 38 RCTs encompassing 2280 patients. The use of rhBNP in the perioperative period significantly enhanced LVEF compared to the control group (mean difference = 3.13 (95% CI [1.88, 4.37]; Conclusions: These findings underscore the potential benefits of rhBNP as a perioperative treatment in patients undergoing cardiac surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.